Plain-English translation of NCT05941741 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new combination approach for advanced nasopharyngeal cancer (a type of cancer in the back of the throat). The study compares two treatment plans: one using cadonilimab (an immunotherapy drug) combined with and radiation, versus the standard and radiation alone. Researchers want to see if adding the medication and low-dose radiation helps more patients recover better and live longer.
Advanced nasopharyngeal cancer is difficult to treat, and many patients still face recurrence even after standard treatment. This trial exists to see if the new immunotherapy medication can help the body's immune system fight the cancer more effectively when combined with radiation and .
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll be randomly assigned to one of two treatment groups. Both groups receive first, followed by radiation therapy combined with . The new treatment group also receives the immunotherapy medication and low-dose radiation as part of their plan. You'll have regular clinic visits for treatment and monitoring, blood tests to check your health, and scans to see how the cancer is responding. The study team will also track side effects and your quality of life throughout the treatment.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China